Analysts Rally Behind Bayer as Ruveon Restructuring and Court Ruling Reshape Risk
Published on 07/06/2026 at 12:42 | Redaktion boerse-global.de
Bayer’s decision to hive off its controversial US glyphosate business into a standalone entity called Ruveon LLC has triggered a wave of analyst upgrades that mark a decisive shift in how the market prices the pharmaceutical and crop-science giant. Both Goldman Sachs and Deutsche Bank have raised their price targets sharply, citing a fundamentally lower legal risk profile following a recent Supreme Court ruling and the operational separation of Roundup-related liabilities.
Ruveon, based in St. Louis and formally launched on July 1, 2026, now controls all US sales of the weedkiller. The move is designed to wall off future litigation from Bayer’s core operations. Already the new subsidiary has taken an aggressive step, filing an antidumping petition against cheap glyphosate imports from China — a sign that management intends to use the entity for more than just legal insulation.
The legal landscape shifted dramatically on June 26, when the US Supreme Court overturned a Missouri state court verdict that had centred on inadequate warning labels. That decision effectively blocks thousands of similar claims, though it does not eliminate all litigation categories. Claims based on defective product design or negligence remain viable, leaving a residual layer of uncertainty that the Ruveon structure aims to contain.
Analyst responses were swift. Goldman Sachs’ James Quigley lifted his target from €55 to €62.50, keeping a buy rating. He cut his estimate for Bayer’s cost of capital and reduced the valuation discount applied to the pharmaceuticals division, reflecting what he sees as a materially improved risk profile. Two days earlier, Deutsche Bank had raised its target from €45 to €60 and upgraded the stock from hold to buy, joining a growing chorus of positive ratings.
Should investors sell immediately? Or is it worth buying Bayer?
The stock has absorbed these endorsements with a near-record rally. On Friday it closed at €53.04, just 1.5% shy of its 52-week high of €53.86. Over the past 30 days the share price has surged 47.54%, and on a trailing 12-month basis the gain now stands at 103.57%. Since the start of 2026, Bayer has added 39.49% — one of the best performances in the German equity market this year.
That meteoric rise has brought the chart technicians to the fore. The relative strength index hit 85.1 on Friday, deep in overbought territory and well above the threshold that typically precedes a pullback. The distance to the 200-day moving average, at 37.11, has stretched to nearly 43%. Such extremes have historically triggered either a correction or an extended period of consolidation. The immediate support to watch lies at the 50-day average of €38.86.
The next major catalyst arrives on August 19, when a US court is scheduled to hear arguments on the proposed glyphosate settlement worth $7.25 billion. Should the judge give final approval, the fundamental overhang that has weighed on Bayer for years would largely dissolve. A rejection, however, risks derailing the entire rally that has been built on hopes of legal closure.
Bayer at a turning point? This analysis reveals what investors need to know now.
For now, the bull case rests on the combination of a cleaner legal trajectory, a clearer corporate structure, and analyst targets that still offer upside from current levels. Whether the technical warning signs prove to be a brief pause or the start of a deeper retracement will likely be decided in the run-up to that August hearing — and in whether the market continues to buy the logic of Bayer’s new, leaner risk picture.
Ad
Bayer Stock: New Analysis - 6 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
